retatrutide mechanism triple agonist glp-1 gip glucagon phase 3 2025 Retatrutide Retatrutide: The triple agonist powering
Description
Current evidence suggests these are long-term treatments, similar to blood pressure or cholesterol medications
Outcomes Figure 1 shows the network of comparisons for the outcomes
Mapelli, C
Get notified of new episodes
IUPHAR reviewglucagon-like peptide-1 (GLP-1) and substance use disorders: an emerging pharmacotherapeutic target
